Perceptronix Receives CE Mark for its First Product
February 2, 2006
VANCOUVER, CANADA (February 2, 2006) – Perceptronix Medical Inc. (“Perceptronix”) announced today that it has received CE Mark for its first product – the ClearCyte™ quantitative pathology system, allowing it to be marketed throughout the European Union (EU).
ClearCyte™ is a high throughput automated image cytometer, used to measure DNA properties in cell samples of different tissues, such as bladder washings, breast nipple aspirates, oesophagus touch preparations, bronchial washings/brushings, oral brush-biopsies, etc. Combined with interactive review of cells, ClearCyte™ tests may provide valuable information related to the clinical diagnosis and prognosis of cancer.
“We are pleased to have successfully completed this market access milestone for our first product. ClearCyte™ is designed for high throughput clinical laboratory testing and we believe that the receipt of CE Mark will accelerate our negotiations with potential clinical laboratory partners throughout Europe. We have also recently submitted a license application to Health Canada.” said Dr. Alexei Doudkine, Product Director, Quantitative Pathology Systems for Perceptronix.
About Perceptronix Medical Inc.
Perceptronix (www.perceptronix.com) is a private cancer diagnostics company based in Vancouver, Canada. The Company’s goal is to commercialize technologies to improve the early detection, localization and diagnosis of cancer, with an initial focus on lung cancer. Perceptronix was founded in 1999 to commercialize early cancer detection technologies developed in partnership with the BC Cancer Agency (www.bccancer.bc.ca), a world-leader in cancer care and research, with a particularly notable track record in pioneering early cancer detection programs.
Contact:
Susan Grose
Corporate Secretary
Perceptronix Medical Inc.
Ste. 400, 555 West 8th Avenue
Vancouver, Canada V5Z 1C6
Phone: (604) 707 – 9037
info@perceptronix.com
